Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe

Objectives: Lisdexamfetamine dimesylate (LDX) is approved in some European countries for the second-line treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents when response to previous methylphenidate (MPH) treatment is considered clinically inadequate, and as a fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Siffel, Csaba, Page, Matthew, Maxwell, Tricia, Thun, Barbara, Kolb, Nikolaus, Rosenlund, Mats, von Bredow, Dorothea, Keja, Jacco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475084/
https://www.ncbi.nlm.nih.gov/pubmed/32315539
http://dx.doi.org/10.1089/cap.2019.0173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475084/
https://www.ncbi.nlm.nih.gov/pubmed/32315539
http://dx.doi.org/10.1089/cap.2019.0173

Ejemplares similares